View - ResearchSpace@Auckland - The University of Auckland

Goldberg, S., C. Springer, et al. (2001). "Can peak expiratory flow measurements estimate
small airway function in asthmatic children?" eb! 120(2):482-8.
Goldman, M. (2007). "Translational mini-review series on Toll-like receptors: Tolllike
receptor ligands as novel pharmaceuticals for allergic disorders." Clinical &
Experimental Immunology 147 (2): 208-16.
Goldstein, M. F., B. A. Yeza, et al. (2001). "Comparisons of peak diurnal expiratory flow
variation, postbronchodilator FEV(l) responses, and methacholine inhalation
challenges in the evaluation of suspected asthma." Chest 119(a): 1001-10.
Gonzalez, C., C. Barroso, et al. (L997). "Neuronal nitric oxide synthase activation by
vasoactive intestinal peptide in bovine cerebral arteries." Journal of Cerebral Blood
Flow & Metabolism 17(9):977-84.
Gonzalez, M. C., P. Diaz, et al. (1987). "Allergen-induced recruitment of bronchoalveolar
helper (OKT4) and suppressor (OKT8) T-cells in asthma. Relative increases in OKT8
cells in single early responders compared with those in late-phase responders."
American Review of RespiratorllDisease 136(3): 600-4.
Gordian, M. E., H. Ozkaynak, et al. (1996). "Particulate air pollution and respiratory disease
in Anchorage, Alaska." Environmental Health Perspectives 104(3): 290-7.
Gorelick, M. H., M. W. Stevens, et al. (2004). "Difficulty in obtaining peak expiratory flow
measurements in children with acute asthma." Pediatric Emergency Care 20(l):22-6.
Gotoh, T. and M. Mori (1999). "Arginase II downregulates nitric oxide (NO) production and
prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells."
Journal of Cell Biology 144(3):427-34.
Goureau, O., M. lrpoivre, et al. (1993). "Differential regulation of inducible nitric oxide
synthase by fibroblast growth factors and transforming growth factor beta in bovine
retinal pigmented epithelial cells: inverse correlation with cellular proliferation."
Proceedings of the National Academy of Sciences of the United States of America
90(9): 4276-80.
Graham, D., A. lrversha, et al. (2001). The Top l0 Report. Top l0 issues affecting the health
and wellbeing of children and young people in Auckland and Waikato. Hamilton,
Waikato District Health Boudr72.
Graham, L. M. (2006). "Classifying asthma." Chest 130(1 Suppl): 13S-20S.
Grant, C. (2006). What does pneumonia cost New Zealand? Trying to Catch Our Breath. I. A.
C. Byrnes. Wellington, New Zealand, Asthma & Respiratory Foundation of New
Tx,aland.:35-39.
Grant, C., A. Pati, et al. (2001). "Ethnic comparisons of disease severity in children
hospitalized with pneumonia in New Zealand." J Paediatr Child Health 37(l):32-7.
Grant, C. C. (2000). "Controlling pertussis in New 7*aland by improving our immunisation
rate." N Z Med J 113(l lll): 228-30.
Grasemann, H., S. S. Gartig, et al. (1999). "Effect of L-arginine infusion on airway NO in
cystic fibrosis and primary ciliary dyskinesia syndrome." European Respiratory
Journal 13(l): ll4-8.
Grasemann, H., C. Grasemann, et al. (2005). "Oral L-arginine supplementation in cystic
fibrosis patients: a placebo-controlled study." Eurooean Respiratory Journal 25(l):62-
8.
Grasemann, H., I. Ioannidis, et al. (1998). "Nitric oxide metabolites in cystic fibrosis lung
disease." Archives of Disease in Childhood. Jan 78(1): 49-53.
Grasemann, H., F. Kurtz, et al. (2006). "Inhaled L-arginine improves exhaled nitric oxide and
pulmonary function in patients with cystic fibrosis." American Journal of Respiratory
& Critical Care Medicine 174(2):208-12.
Grasemann, H., H. Lax, et al. (20O4). "Dornase alpha and exhaled NO in cystic fibrosis."
Pediatric Pulmonology 38(5): 379-85.
299